Pharmaceutical News

RSS

Researchers develop possible new method for treating pancreatic cancer

A possible new method for treating pancreatic cancer which enables the body's immune system to attack and kill cancer cells has been developed by researchers.

22 Dec 2013

Lilly, Boehringer Ingelheim announce FDA acceptance of NDA filing for new insulin glargine product

Eli Lilly and Company and Boehringer Ingelheim today announced that the U.S. Food and Drug Administration has accepted the filing of the New Drug Application for LY2963016, an investigational basal (long-acting) insulin.

21 Dec 2013

Orenitram Extended-Release Tablets get FDA approval for pulmonary arterial hypertension treatment

United Therapeutics Corporation announced today that the United States Food and Drug Administration has approved Orenitram (treprostinil) Extended-Release Tablets for the treatment of pulmonary arterial hypertension in WHO Group I patients to improve exercise capacity.

21 Dec 2013

Moberg Pharma acquires three OTC brands from Bayer HealthCare

On December 6, 2013, Moberg Pharma announced the acquisition of three Over-The-Counter brands in the U.S. from Bayer HealthCare, LLC.

20 Dec 2013

Physician dispels misconceptions about annual flu vaccine

Dr. Jennifer Caudle is an assistant professor of Family Medicine at the Rowan University School of Osteopathic Medicine. Over the years in her busy medical practice, she's heard just about every possible excuse or misconception about the annual flu vaccine.

20 Dec 2013

Auxilium seeks FDA approval for XIAFLEX sBLA to treat multiple Dupuytren's contracture cords concurrently

Auxilium Pharmaceuticals, Inc., a fully integrated specialty biopharmaceutical company, today announced the submission of a supplemental Biologics License Application to the U.S. Food and Drug Administration requesting approval of XIAFLEX (collagenase clostridium histolyticum, or CCH) for the treatment of multiple Dupuytren's contracture cords concurrently.

20 Dec 2013

Doctors should consider underlying inflammatory conditions when selecting anti-epilepsy drugs, say researchers

Physicians at the Ruhr-Universität Bochum (RUB) have been investigating if established anti-epilepsy drugs have anti-inflammatory or pro-inflammatory properties - an effect for which these pharmaceutical agents are not usually tested.

20 Dec 2013

Submicrometer line focusing reduces protein crystal damage, enhances drug development

New recommendations for using X-rays promise to speed investigations aimed at understanding the structure and function of biologically important proteins - information critical to the development of new drugs.

20 Dec 2013

New research assesses nanomedicine-based approaches for treating cancer

As cancer maintains its standing as the second leading cause of death in the U.S., researchers have continued their quest for safer and more effective treatments. Among the most promising advances has been the rise of nanomedicine, the application of tiny materials and devices whose sizes are measured in the billionths of a meter to detect, diagnose and treat disease.

20 Dec 2013

Researchers develop oral vaccine against Helicobacter pylori

Researchers from Southern Medical University in Guangdong, Guangzhou, China, have developed an oral vaccine against Helicobacter pylori, the bacteria responsible for peptic ulcers and some forms of gastric cancer, and have successfully tested it in mice. The research is published ahead of print in the journal Clinical and Vaccine Immunology.

20 Dec 2013

BCG vaccine highly protective against pulmonary TB: Study

The BCG vaccine has been found to be more effective against the most common form of tuberculosis than previously thought, according to a new study in Clinical Infectious Diseases.

20 Dec 2013

Takeda to acquire exclusive license to develop Natrogen's Natura-alpha compound

Takeda Pharmaceutical Company Limited and Natrogen Therapeutics International, Inc. jointly announced today an agreement whereby Takeda will acquire an exclusive license to develop Natrogen's Natura-alpha compound as well as an option to acquire Natrogen. Natura-alpha is a synthetic small molecule oral compound that is believed to inhibit pro-inflammatory cytokine expression, which may help to reduce gastrointestinal inflammation. Natura-alpha is currently in Phase 2 development for the treatment of ulcerative colitis.

20 Dec 2013

FDA approves Baxter's FEIBA for prophylactic treatment of hemophilia patients with inhibitors

Baxter International Inc. today announced that the United States Food and Drug Administration granted approval of Baxter's FEIBA [Anti-Inhibitor Coagulant Complex], the first and only FDA-approved treatment for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in patients with hemophilia A or B who have developed inhibitors.

From Baxter International Inc. 20 Dec 2013

Australian Therapeutic Goods Administration approves Genzyme's Lemtrada for multiple sclerosis

Genzyme, a Sanofi company, announced today that the Australian Therapeutic Goods Administration has approved Lemtrada (alemtuzumab) for the treatment of relapsing forms of multiple sclerosis for patients with active disease defined by clinical or imaging features to slow the accumulation of physical disability and reduce the frequency of clinical relapses.

19 Dec 2013

GSK team wins Drug Discovery of Year award for developing trametinib for malignant melanoma

The British Pharmacological Society proudly announces that its Drug Discovery of the Year award has been won by the team at GlaxoSmithKline (GSK) responsible for the development of trametinib - a new treatment for malignant melanoma (a type of skin cancer).

19 Dec 2013

Daiichi Sankyo submits LIXIANA supplemental NDA for review in Japan

Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that it has submitted a supplemental New Drug Application for its oral, once-daily direct factor Xa-inhibitor LIXIANA® (Edoxaban Tosilate Hydrate) for review by the Japanese Ministry of Health, Labour and Welfare. Daiichi Sankyo is seeking approval in Japan for edoxaban in new indications for non-valvular atrial fibrillation and symptomatic venous thromboembolism.

19 Dec 2013

Nuvo Research, NovaMedica enter into agreement to market Pennsaid products in Russia

Nuvo Research Inc., a specialty pharmaceutical company with a diverse portfolio of products in the areas of topical pain and immunology, and NovaMedica LLC, a Russian pharmaceutical company, today announced that they have signed a supply and distribution agreement providing NovaMedica the exclusive rights to market and sell Nuvo's Pennsaid 1.5% and Pennsaid 2% products in Russia and some of the Community of Independent States.

19 Dec 2013

Helsinn, Mundipharma sign distribution and license agreement for investigational therapy

Helsinn and Mundipharma announce the signature of a new, exclusive license and distribution agreement, covering China, Hong Kong and Macao, for netupitant-palonosetron fixed dose combination, a Helsinn product under development for the treatment of chemotherapy-induced nausea and vomiting.

19 Dec 2013

Meda inks agreement to acquire ZpearPoint AS

Meda has signed an agreement to acquire ZpearPoint AS, including global rights to its main product, EB24, an OTC line for treating dental erosion. Dental erosion is a common, growing condition that impacts all ages and for which there is currently no effective treatment. The condition is estimated to affect 15-50% of the population and it is sometimes referred to as the "new caries".

19 Dec 2013

Scientists report new development toward long-sought insulin pill for diabetes treatment

Since insulin's crucial discovery nearly a century ago, countless diabetes patients have had to inject themselves with the life-saving medicine. Now scientists are reporting a new development toward a long-sought insulin pill that could save millions the pain of daily shots. Published in the ACS journal Biomacromolecules, the advance could someday not only eliminate the "ouch" factor, but also get needle-wary - and weary - patients to take their medicine when they should.

19 Dec 2013

Pharmaceutical News

Researchers develop possible new method for treating pancreatic cancer

Lilly, Boehringer Ingelheim announce FDA acceptance of NDA filing for new insulin glargine product

Orenitram Extended-Release Tablets get FDA approval for pulmonary arterial hypertension treatment

Moberg Pharma acquires three OTC brands from Bayer HealthCare

Physician dispels misconceptions about annual flu vaccine

Auxilium seeks FDA approval for XIAFLEX sBLA to treat multiple Dupuytren's contracture cords concurrently

Doctors should consider underlying inflammatory conditions when selecting anti-epilepsy drugs, say researchers

Submicrometer line focusing reduces protein crystal damage, enhances drug development

New research assesses nanomedicine-based approaches for treating cancer

Researchers develop oral vaccine against Helicobacter pylori

BCG vaccine highly protective against pulmonary TB: Study

Takeda to acquire exclusive license to develop Natrogen's Natura-alpha compound

FDA approves Baxter's FEIBA for prophylactic treatment of hemophilia patients with inhibitors

Australian Therapeutic Goods Administration approves Genzyme's Lemtrada for multiple sclerosis

GSK team wins Drug Discovery of Year award for developing trametinib for malignant melanoma

Daiichi Sankyo submits LIXIANA supplemental NDA for review in Japan

Nuvo Research, NovaMedica enter into agreement to market Pennsaid products in Russia

Helsinn, Mundipharma sign distribution and license agreement for investigational therapy

Meda inks agreement to acquire ZpearPoint AS

Scientists report new development toward long-sought insulin pill for diabetes treatment

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Latest News